Vivat Therapeutics is a biopharmaceutical company developing disease-modifying therapies for the diseases and conditions of aging.
The population over 60 is set to double within a generation, placing unprecedented demand on individuals and health systems alike.
People are living longer, but too many of those added years are spent in declining health rather than good health.
Many of the most burdensome conditions of aging are still managed symptomatically, with no therapy that modifies the underlying disease.
A growing body of science points to common cellular drivers underlying many age-related diseases. Vivat is advancing a novel, proprietary small-molecule program designed to target that biology — with the potential to modify disease across several major indications.
We aim beyond symptom management — toward therapies that alter the course of the diseases of aging.
Our program is grounded in preclinical models with objective endpoints designed to predict human benefit.
We are advancing a lead candidate toward a first-in-human study, starting with a well-defined initial indication.
Success in the initial indication opens a pipeline across multiple large, underserved age-related diseases.
Founder, CEO and Chairman of Ariad Pharmaceuticals; former CEO of Rinat Neuroscience (acquired by Pfizer).
Former CEO of Geron Corporation (startup through IPO) and Arena Bioworks; Senior Advisor at EW Healthcare Partners.
30 years in pharmaceutical development with 12 NDA approvals; co-founder and COO of Oncoethix (sold to Merck).
Management accountant with two decades across finance, accounting and systems management; CFO of Cthulhu Ventures.
Co-founder, CEO and Chairman of Babcock & Brown; Founder and CEO of Cthulhu Ventures.
We welcome conversations with investors, partners, and scientists who share our commitment to extending healthspan.
info@vivattherapeutics.com